Bone Biologics Corp

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations

	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Revenues · $ · - · $ · - · $ · - · $ · -
Operating expenses
Research and development	187,808	429,747	802,994	1,025,814
General and administrative	527,466	521,274	1,698,843	1,638,409
Total operating expenses	715,274	951,021	2,501,837	2,664,223
Loss from operations	(715,274)	(951,021)	(2,501,837)	(2,664,223)
Other income (expenses)
Change in fair value of warrant liability	1,212	(9,974)	3,469	38,122
Interest income	47,325	19,993	74,020	35,396
Total other income	48,537	10,019	77,489	73,518
Net loss	(666,737)	(941,002)	(2,424,348)	(2,590,705)
Deemed dividend on warrant inducements	-	(3,212,504)	-	(3,212,504)
Net loss attributable to common stockholders	$(666,737)	$(4,153,506)	$(2,424,348)	$(5,803,209)
Weighted average shares of common outstanding – basic and diluted(1)	1,795,097	292,321	965,800	199,469
Loss per share – attributable to common stockholders, basic and diluted(1)	$(0.37)	$(14.21)	$(2.51)	$(29.09)

(1)	Adjusted to reflect the reverse stock split as described in Note 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.